Bútová, R.; Vychytilová-Faltejsková, P.; Gregorová, J.; Radová, L.; Almáši, M.; Bezděková, R.; Brožová, L.; Jarkovský, J.; Knechtová, Z.; Štork, M.;
et al. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines 2021, 9, 1637.
https://doi.org/10.3390/biomedicines9111637
AMA Style
Bútová R, Vychytilová-Faltejsková P, Gregorová J, Radová L, Almáši M, Bezděková R, Brožová L, Jarkovský J, Knechtová Z, Štork M,
et al. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines. 2021; 9(11):1637.
https://doi.org/10.3390/biomedicines9111637
Chicago/Turabian Style
Bútová, Romana, Petra Vychytilová-Faltejsková, Jana Gregorová, Lenka Radová, Martina Almáši, Renata Bezděková, Lucie Brožová, Jiří Jarkovský, Zdeňka Knechtová, Martin Štork,
and et al. 2021. "LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients" Biomedicines 9, no. 11: 1637.
https://doi.org/10.3390/biomedicines9111637
APA Style
Bútová, R., Vychytilová-Faltejsková, P., Gregorová, J., Radová, L., Almáši, M., Bezděková, R., Brožová, L., Jarkovský, J., Knechtová, Z., Štork, M., Pour, L., & Ševčíková, S.
(2021). LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines, 9(11), 1637.
https://doi.org/10.3390/biomedicines9111637
